This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BBS-Bioactive Bone Substitutes Oyj Valuation

Is BONEHN0124 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BONEHN0124 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BONEHN0124's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BONEHN0124's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BONEHN0124?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BONEHN0124. This is calculated by dividing BONEHN0124's market cap by their current preferred multiple.
What is BONEHN0124's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	€6.29m

BONEHN0124 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BONEHN0124's PB Ratio compare to its peers?

The above table shows the PB ratio for BONEHN0124 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.4x
APTX Aptinyx	0.4x	n/a	US$6.5m
PCIB PCI Biotech Holding	2x	n/a	NOK 64.1m
RESP Respiratorius	2.6x	n/a	SEK 69.9m
CYCN Cyclerion Therapeutics	0.7x	n/a	US$6.3m
BONEHN0124 BBS-Bioactive Bone Substitutes Oyj	1.7x	n/a	€6.3m

Price-To-Book vs Peers: BONEHN0124 is expensive based on its Price-To-Book Ratio (1.7x) compared to the peer average (1.4x).

Price to Earnings Ratio vs Industry

How does BONEHN0124's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.0%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: BONEHN0124 is good value based on its Price-To-Book Ratio (1.7x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is BONEHN0124's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BONEHN0124 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BONEHN0124's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.